İlke AKIN MUNGAN, Emel OKULU, Saadet ARSAN, Tomris TÜRMEN, Gül KAZANCI, Begüm ATASAY

Yenidoğanda nadir görülen bir anestezi komplikasyonu: malin hipertermi

Malin hipertermi, anestezi ile ilişkili nadir görülen ancak ölümcül olabilen bir hastalıktır. Burada genel anestezi sonrası, malin hipertermi gelişen ve dantrolen tedavisi ile düzelen bir yenidoğan olgusu sunulmaktadır. Hastaya genel anestezi altında üst hava yollarının muayenesi planlanarak sevofluran ile anestezi uygulanmıştı. Anesteziden bir saat sonra hastada hipertermi, taşikardi, takipne ve kas rijiditesi gelişti, klinik ve laboratuvar bulguları ile malin hipertermi tanısı konuldu. Dantrolen tedavisi ile hastadaki bulgular dramatik olarak düzeldi.

A rare complication of anesthesia in newborn: malignant hyperthermia

Malign hyperthermia is a rare anesthesia-related disorder which may be fatal. Here, we present a newborn who developed malign hyperthermia after general anesthesia and recovered with dantrolene treatment. Anesthesia with sevoflurane was performed in the patient planning examination of the upper airways under general anesthesia. One hour after anesthesia the patient developed hyperthermia, tachycardia, tachipnea and muscle rigidity and a diagnosis of malignant hyperthermia was made with clinical and laboratory findings. The findings improved dramatically with dantrolene treatment.

PDF

___

1. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2007; 2: 21.
2. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-9.
3. Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000; 85: 118-28.
4. Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Registry. Anesthesiology 1992; 76: 16-27.
5. Chamley D, Pollock AN, Stowell KM, Brown RL. Malignant hyperthermia in infancy and identification of novel RYR1 mutation. Br J Anaesth 2000; 84: 500-4.
6. Hsu SC, Huang WT, Yeh HM, Hsich AYJ. Suspected malignant hyperthermia during sevoflurane anesthesia. J Chin Med Assoc 2007; 70: 507-10.
7. Nelson TE. Porcine malignant hyperthermia: critical temperatures for in vivo and in vitro responses. Anesthesiology 1990; 73: 449-54.
8. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia, the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997; 41: 955-66.
9. Allen GC, Larach MG, Kunselman AR. The sensitivity and spesificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 1998; 85: 579-88.
10. Migita T, Mukaida K, Kawamoto M, Kobayashi M, Nishino I, Yuget O. Propofol-induced changes in myoplasmic calcium concentrations in cultured human skeletal muscles from RYR1 mutation carriers. Anaesth Intensive Care 2007; 35: 894-8.
11. Girard T, Litman RS. Molecular genetic testing to diagnose malignant hyperthermia susceptibility. J Clin Anesthesia 2008; 20: 161-3.
12. Anderson-Pompa K, Foster A, Parker L, et al. Genetics and susceptibility to malignant hyperthermia. Crit Care Nurse 2008; 28: 32-6.
13. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene-a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59: 364-73.
14. Rosenberg H, Fletcher JE. An update on the malignant hyperthermia syndrome. Ann o Acad Med Singapore 94; 23: 84-97.